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CORRESPONDENCE 
Clarifying the relationship between Metformin, Acute Kidney Injury and Lactic Acidosis 
Samira Bell1,2, Enrique Soto-Pedre3, Paul Connelly3, Shona Livingstone4 & Ewan Pearson3 
We read, with interest, the News and Views article by C. Rhee and K. Kalanter-Zadeh (Diabetes 
mellitus: Complex interplay between metformin, AKI and lactic acidosis. Nat. Rev. Nephrol. 13, 521–
522; 2017)1, which discusses our recent work looking at the relationship between metformin, acute 
kidney injury (AKI), and lactic acidosis2,3. In response to this discussion of some of our findings we 
would like to highlight several points  
First, Connelly et al. demonstrated that 80% of lactic acidosis within the study cohort occurred in the 
presence of AKI3. In view of the effectiveness of treatment and increasing evidence of the beneficial 
cardiovascular effects of metformin, we feel that metformin should be only temporarily 
discontinued in patients with a condition that predisposes them to acute AKI; this advice is similar to 
the advice given for ACE inhibitors and angiotensin receptor blockers.  
Second, although we acknowledge the difficulties of accurately identifying metformin-associated 
lactic acidosis (MALA) cases in observational studies, we do not agree that the crude incidence rate 
of lactic acidosis observed in the study by Connelly et al. is biased because it differs from rates 
reported by others. Instead, we would like to emphasize that crude incidence rates disregard the 
structure of the population. Thus, comparing crude incidence rates alone can be misleading before 
standardization is carried out to remove the effect of differential structures in populations under 
comparison.  
Third, it was also suggested that the absence of a ‘new-user’ design in the study by Bell et al.2 may 
not have accounted for patients who stopped using metformin or died due to its adverse effects 
before study entry, biasing results towards a protective effect. Our study population comprised of 
63% incident users over a long period, making survivor bias a less likely explanation for our findings.   
Fourth, the elevated risk of developing AKI that is associated with ‘ever’ having been on or currently 
being on metformin is due to within and between person allocation bias, where being prescribed 
metformin is a marker for other co-morbidities making the patient more vulnerable to AKI. The fact 
that AKI incidence is not elevated in patients during periods on the drug compared with periods off 
the drug, suggests that the drug itself is not increasing the risk of AKI.  
Finally, we do not agree with the recommendation made by C. Rhee and K. Kalanter-Zadeh that the 
use of metformin should be restricted in patients with chronic kidney disease (CKD), particularly in 
view of the increasing evidence base that supports metformin safety in CKD4,5. We eagerly await 
further pharmacokinetic studies on the safety and efficacy of metformin in these patients.  
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